CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug 

RegulatoryCRLNegative
AI Analysis

Summary

Hikma is investing $267 million to expand its manufacturing facility in Ohio, while Cingulate received a Complete Response Letter for its ADHD drug candidate.

Outcome Details

Complete Response Letter received for ADHD drug

Importance:6/10
Sentiment:
-0.30
regulatoryADHDcapital_investmentmanufacturingCRL
Related Companies

Read the original article

Published by Endpoints News on June 4, 2026 3:42 PM

Read Original